thrombocythemia carrying the JAK2 (617V>F) mutation Increased risk of pregnancy complications in patients with essential

[1]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[2]  J. Spivak,et al.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. , 2006, Blood.

[3]  François Girodon,et al.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.

[4]  M. Griesshammer,et al.  Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. , 2006, Seminars in thrombosis and hemostasis.

[5]  A. Schafer.  Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. , 2006, Blood.

[6]  P. Guglielmelli,et al.  A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis , 2006, Leukemia.

[7]  M. Cazzola,et al.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.

[8]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[9]  M. Wadleigh,et al.  JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance , 2005, British journal of haematology.

[10]  C. Harrison.  Pregnancy and its management in the Philadelphia negative myeloproliferative diseases , 2005, British journal of haematology.

[11]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[12]  R. Kaaja,et al.  Pregnancy in essential thrombocythaemia: experience with 40 pregnancies , 2004 .

[13]  M. Cazzola,et al.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.

[14]  A. Tefferi,et al.  Thrombocythaemia and pregnancy. , 2003, Best practice & research. Clinical haematology.

[15]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[16]  D. Vanstraelen,et al.  Management of Essential Thrombocythemia during Pregnancy with Aspirin, Interferon Alpha-2a and No Treatment , 2002, Acta Haematologica.

[17]  U. Seligsohn,et al.  Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.

[18]  A. Tefferi,et al.  A single institutional experience with 43 pregnancies in essential thrombocythemia , 2001, European journal of haematology.

[19]  A. Tefferi,et al.  Long-term use of anagrelide in young patients with essential thrombocythemia. , 2001, Blood.

[20]  M. Bangerter,et al.  Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies , 2000, European journal of haematology.

[21]  A. Many,et al.  Increased frequency of genetic thrombophilia in women with complications of pregnancy. , 1999, The New England journal of medicine.

[22]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[23]  A. Tefferi,et al.  Outcome analysis of 34 pregnancies in women with essential thrombocythemia. , 1995, Archives of internal medicine.

[24]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[25]  T. Barbui,et al.  Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Laszlo,et al.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.

[27]  R. Hoffman,et al.  Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  P. Bockenstedt.  Management of hereditary hypercoagulable disorders. , 2006, Hematology. American Society of Hematology. Education Program.

[29]  J. Laszlo,et al.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.

[30]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.